Clinical Research Directory
Browse clinical research sites, groups, and studies.
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Sponsor: Peking University People's Hospital
Summary
To investigate the efficacy of interferon-α prophylaxis in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with TP53 mutation who were negative for minimal residual disease (MRD) by flow cytometry within 2 months after allogeneic hematopoietic stem cell transplantation. To explore the efficacy of interferon-α in reducing the relapse rate of AML/MDS patients with TP53 mutation after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Official title: Interferon-α for Preventing Relapse in TP53+ Myeloid Malignancy Post Allo-HSCT
Key Details
Gender
All
Age Range
12 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2024-01-01
Completion Date
2026-06-30
Last Updated
2025-06-03
Healthy Volunteers
No
Interventions
IFN-Α
Leukemia-associated immunophenotyping (LAIPs) was performed by flow cytometry at +1 month and +2 month after HSCT. If MRD was negative on two consecutive flow cytometry assays, interferon-α prophylaxis was initiated on day +75 after transplantation, and cyclosporine was tapered on day +100 after transplantation. The dose of interferon-α was 3 million units/time, subcutaneously injected twice a week. Cycles were given every 4 weeks until hematologic relapse or up to 6 cycles.
Locations (1)
Deparment of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China